mutation rate were found between histological and pathological subtypes (P<0.05). 2 There were significant differences between KRAS mutation and invasive adenocarcinoma types (P<0.05). Moreover, the mutation rate was higher in invasive mucinous adenocarcinoma. 3 The relationship between EGFR mutation abundance and clinical features: taking 20% mutation abundance as cutoff value, the mutation abundance of EGFR showed no significant difference with neither of the following: gender (P¼0.0.246), age (P¼0.453), smoking history (P¼1.00), tumor stage (Z¼-0.500, P¼0.617). Conclusion: 1 The rate of EGFR mutation is significantly different among different pathological subtypes of lung adenocarcinoma. The frequency of EGFR mutation is higher in acinar and papillary adenocarcinoma, while lower in invasive mucinous adenocarcinoma. The mutation rate of KRAS was higher in invasive mucinous adenocarcinoma. To sum up, the relationship between the mutation status of the driving gene and the pathological subtype of lung adenocarcinoma is not very clear. This study provides a novel perspective for the following exploration of the correlation between pathological subtypes, stages and other clinical data and the mutation status. 2 In lung adenocarcinoma, the mutation abundance of EGFR gene was not significantly associated with age, gender, tumor stage, and smoking history. 3 Next generation sequencing technology can rapidly, sensitively and accurately detect the mutation status and abundance of EGFR, KRAS and other genes.
Background: ALK rearrangement and EGFR alterations are oncogenic driver mutations in lung cancers. Generally considered mutually exclusive, some studies suggested that these two mutations might occur concomitantly. Limited studies have reported the underlying association of molecular features and drug response to EGFR-TKIs in lung cancers with such co-alterations. Here, we performed next-generation sequencing (NGS) analysis in Chinese lung cancer patients, and evaluated distinct features of EML4-vs. non-EML4-ALK fusions in EGFR-mutated cases. Method: A retrospective review was performed on genomic profiling data from either tissue or plasma of 419 ALK-rearranged lung cancer patients, sequenced in a CLIA-certified laboratory from 2015 to 2017. Patient characteristics (n¼21) and clinical outcomes of patients harboring concurrent EGFR and ALK alterations were collected. Results: Among the 419 ALK-rearranged lung cancers, a total of 21 patients (5.01%) were detected harboring concurrent ALK and EGFR (exon 18-20) genomic alterations. The concomitant rate of EGFR in patients harboring EML4-ALK (3.06%, 11/359) was dramatically lower than in non-EML4-ALK patients (16.67%, 10/60, p<0.001). Four EML4-ALK and 1 non-EML4-ALK patients were found to have de novo ALK/EGFR co-mutations whereas 1 EML4-ALK and 3 non-EML4-ALK patients acquired their ALK alterations after EGFR TKI treatment. For dual-positive patients who received past EGFR-TKI with unknown ALK status before the treatment, EML4-ALK/EGFR patients (n¼6) commonly had shorter PFS to EGFR-TKI as well as higher relative ALK/EGFR allele frequency compared to non-EML4-ALK/EGFR (n¼6; mPFS, 5.45 vs 15 months, p¼0.11; mRAF, 1.52 vs 0.41, p¼0.01), suggesting that EML4-ALK was more likely to be de novo whereas non-EML4-ALK acquired after EGFR-TKI. In addition, we found that for 9 dual-positive patients who had prior first-generation EGFR-TKI treatment, the clinical efficacy of single TKI use varied greatly, and patients might benefit from combination therapy of ALK+EGFR TKIs. Conclusion: This study revealed that EML4-ALK/EGFR and non-EML4-ALK/EGFR co-alterations displayed distinct prevalence in Chinese lung cancer patients. Our analyses suggested that non-EML4-ALK might be an acquired gene alteration and function as a resistance mechanism to EGFR-TKI, which might explain the observed discrepancy in prevalence as our sequencing cohort consisted of both previously treated or untreated patients. In addition, we observed that patients with dual ALK/EGFR alterations may benefit from combinatorial TKIs therapy. Background: 2% -7% NSCLC patients were detected to have ALK mutation. At present, two or more generations ALK inhibitors have been used for ALK positive NSCLC treatment which including crizotinib, alectinib, ceritinib, brigatinib and so on. Although, most of the adverse events (AEs) of ALK inhibitors are grade 1 to grade 2 and can be generally well tolerated, the serious adverse events (SAEs) of ALK inhibitors are lack of huge data analysis as we know and the lung toxicity of ALK inhibitors is needed to be payed attention to. Thus, we performed metaanalysis to evaluate the safety of ALK inhibitors and especially the SAEs. Method: 16 studies from 4 database (Pubmed, Science Direct, ClinicalTrials.gov and Cochrane Library) were included in this meta-analysis. All statistical analyses in this meta analysis were performed by STATA 14.0 software. We analyzed the incidence of pooled AEs, the incidence of pooled SAEs and the incidences of common types of SAEs of ALK inhibitors. Results: The pooled AEs of ALK inhibitors almost occurred in all participates and the pooled SAEs occurred in over 20% participates. Especially ceritinib and brigatinib, of which the SAEs occurred in over 40% participates. It is likely that alectinib is safest ALK inhibitors of the two generations ALK inhibitors. Generally, ALK inhibitors shows significant lung toxicity. Conclusion: In conclusion, the ALK related SAEs should draw our attention especially the lung toxicity. According to this meta-analysis, alectinib seems to be the safest ALK inhibitor. Physicians should focus on the related SAEs when using ALK inhibitors. Keywords: serious adverse events, lung toxicity, ALK inhibitors, adverse events
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